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Abstract
Background: Chronic rotator cuff pathology (CRCP) is a common shoulder condition causing
pain and disability. Physiotherapy is often the first line of management for CRCP yet there is little
conclusive evidence to support or refute its effectiveness and no formal evaluation of its cost-
effectiveness.
Methods/Design:  This randomised, double-blind, placebo-controlled trial will involve 200
participants with CRCP recruited from medical practices, outpatient departments and the
community via print and radio media. Participants will be randomly allocated to a physiotherapy or
placebo group using concealed allocation stratified by treating physiotherapist. Both groups will
receive 10 sessions of individual standardised treatment over 10 weeks from one of 10 project
physiotherapists. For the following 12 weeks, the physiotherapy group will continue a home
exercise program and the placebo group will receive no treatment. The physiotherapy program will
comprise shoulder joint and spinal mobilisation, soft tissue massage, postural taping, and home
exercises for scapular control, posture and rotator cuff strengthening. The placebo group will
receive inactive ultrasound and gentle application of an inert gel over the shoulder region. Blinded
assessment will be conducted at baseline and at 10 weeks and 22 weeks after randomisation. The
primary outcome measures are self reported questionnaires including the shoulder pain and
disability index (SPADI), average pain on an 11-point numeric rating scale and participant perceived
global rating of change. Secondary measures include Medical Outcomes Study 36-item short form
(SF-36), Assessment of Quality of Life index, numeric rating scales for shoulder pain and stiffness,
participant perceived rating of change for pain, strength and stiffness, and manual muscle testing for
shoulder strength using a handheld dynamometer. To evaluate cost-effectiveness, participants will
record the use of all health-related treatments in a log-book returned to the assessor monthly. To
test the effect of the intervention using an intention-to-treat analysis, linear regression modelling
will be applied adjusting for baseline outcome values and other demographic characteristics.
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Participant measures of perceived change will be compared between groups by calculating the
relative risks and their 95% confidence intervals at each time point using log binomial regression.
Discussion: Results from this trial will contribute to the evidence regarding the effectiveness of a
physiotherapy program for the management of CRCP.
Trial registration: NIH Clinical Trials Registry # NCT00415441
Background
Shoulder disorders are a common cause of musculoskele-
tal morbidity in the community [1,2], affecting 15–30%
of adults at any one time [3] and having their peak preva-
lence in the mid-to-older age groups [4]. Since moving the
shoulder allows placement of the hand, compromised
shoulder function impacts substantially on tasks essential
to daily living such as dressing, eating, personal hygiene
and work [5]. Shoulder pain often impairs the ability to
sleep, thus affecting mood and concentration. Hence
shoulder disorders can lead to considerable disability,
reductions in health-related quality of life, absenteeism
from work and substantial utilization of health care
resources [5-7].
Shoulder disorders are a common reason for seeking med-
ical care – in Australia, they account for 1.2% of all general
practice encounters, being third only to back (3.8%) and
neck complaints as musculoskeletal reasons for primary
care consultations [8]. They also account for up to 10% of
all referrals to physiotherapists [9]. Shoulder disorders are
often recalcitrant with persisting pain and disability from
12 [10] to 18 months [11] in up to 50% of cases. Chronic
shoulder conditions may require surgical intervention in
15–28% of individuals [12]. Thus, they are a relevant
health problem for clinicians, funding providers and
health-care policy makers.
Although there is controversy as to exact definitions for
different shoulder diagnostic categories, a large propor-
tion of shoulder problems can be classified under the term
'chronic rotator cuff pathology' (CRCP). The term (or its
variants such as impingement syndrome) includes a spec-
trum of pathologies (tears, inflammation, tendonitis,
degeneration) involving contractile and other local struc-
tures around the shoulder joint [13,14] giving rise to sim-
ilar signs and symptoms. Pain is the main feature,
particularly on overhead movement, at night, and when
lying on the affected side. Examination may reveal a pain-
ful arc during shoulder elevation, pain on resisted shoul-
der abduction, external rotation or internal rotation, and
a positive impingement test (ref). Restricted shoulder
range may be present but is mostly related to pain rather
than stiffness per se [15]. Unlike other shoulder condi-
tions, such as adhesive capsulitis, global shoulder passive
restriction is not a feature. Diagnosis is traditionally based
on history and clinical findings. Investigative procedures
such as x-ray, ultrasound or magnetic resonance imaging
may be used to demonstrate CRCP or to exclude other less
common shoulder pathologies.
It is thought that shoulder impingement is involved in the
initiation and/or perpetuation of CRCP. This occurs when
the greater tuberosity impinges against the coracoacro-
mial arch in shoulder elevation causing mechanical irrita-
tion of local structures [15]. While there is speculation as
to whether the pathology seen with CRCP is primary or
secondary to impingement, a number of factors can play
a role in CRCP [15,16]. In particular, if the rotator cuff
muscles do not function in a co-ordinated manner with
each other as well as with the principal muscles that move
the humerus and scapula, then inadequate stabilisation of
the humeral head may occur during shoulder elevation
[17,18]. Poor shoulder, cervical and thoracic posture as
well as tight structures can also contribute to dysfunc-
tional movement patterns [19,20] and ultimately chronic
pathology and pain.
Physiotherapy is often the first line of management for
CRCP [21]. In a survey of approximately 800 primary care
medical practitioners, 79% stated that their usual treat-
ment of a patient with CRCP would be referral to a phys-
iotherapist [21]. Physiotherapy aims to reduce pain and
disability by improving the biomechanics and movement
patterns of the shoulder complex rather than by treating
the pathology per se. In clinical practice, patients with
CRCP receive a combination of physiotherapy interven-
tions in order to effectively address the modifiable factors
contributing to pain and dysfunction.
While physiotherapy is commonly prescribed for CRCP,
at present there is little conclusive evidence to support or
refute its effectiveness, and no formal evaluation of its
cost-effectiveness. In a Cochrane review, 11 trials were
identified that evaluated physiotherapy for CRCP [22].
No firm conclusions were able to be drawn given the var-
iable methodological quality of the trials and the fact that
many tested a single physiotherapy modality with few
testing combined modalities despite this being the most
common way in which shoulder disorders are treated in
practice. Furthermore, eight of the 11 (72%) CRCP trials
evaluated electrotherapy modalities which are generallyBMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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not recommended by expert clinicians as the most appro-
priate physiotherapy modality to treat CRCP. From the tri-
als in CRCP or in mixed shoulder disorders that were
included in the review, there was some evidence to pro-
pose that exercise may be effective, with additional benefit
from mobilisation [23-26]. Recent trials identified since
this Cochrane review still fail to clarify the effectiveness of
physiotherapy for CRCP given differences in the treatment
program, comparison group and outcomes [27-30]. The
need for further clinical trials in this area is supported by
the conclusions and recommendations of other recent
systematic reviews [31-33].
Therefore, the aim of this trial is to determine whether a
10-week multimodal physiotherapy program reflective of
current physiotherapy practice improves pain, disability
and health-related quality of life and is more cost-effective
than placebo in individuals with CRCP.
Methods/Design
Design
This will be a randomised placebo controlled trial with
blinded participants and outcome assessors (Figure 1).
The trial comprises a 10-week intervention and a 12-week
follow-up (Figure 1). Participants will be assessed imme-
diately before treatment (baseline), immediately after
treatment (final) and at 22 weeks (follow-up) post ran-
domisation. The assessments will be performed by the
same assessor who will be blind to group allocation.
Participants
A community sample will be recruited in Melbourne, Aus-
tralia through orthopaedic and rheumatology outpatient
clinics, community-based practices and general practi-
tioners as well as by advertising in print and radio media.
Inclusion criteria will be: (i) aged over 18 years; (ii) shoul-
der pain for greater than 3 months; (iii) pain severity on
movement rated at least 4/10 on an 11 point numeric rat-
ing scale; (iv) pain on active abduction or external rota-
tion and; (v) positive shoulder impingement quick test
[34]. Exclusion criteria will be: (i) resting shoulder pain of
greater than 7/10 in severity; (ii) reason to suspect a com-
plete rotator cuff tear eg. substantial shoulder weakness, a
positive drop-arm sign or a high riding humerus observed
on plain xray; (iii) prior shoulder surgery; (iv) radiological
evidence of shoulder osteoarthritis, shoulder joint calcifi-
cation or prior fracture; (v) systemic pathology including
inflammatory joint disease or neoplastic disorders; (vi)
more than 50% restriction of passive range of motion in
two or more planes; (vii) shoulder pain referred from ver-
tebral structures diagnosed via spinal clearing tests [35];
(viii) symptoms of complex regional pain syndrome; (iix)
active intervention in last 3 months including corticoster-
oid/hydrodilatation injection or physiotherapy; (ix) anti-
inflammatory medication in past two weeks; (x) inability
to understand written and spoken English.
A diagnosis of CRCP by a medical doctor supported by a
plain x-ray of the shoulder will be necessary for potential
inclusion. All volunteers will then be required to undergo
a physical examination with a physiotherapist to screen
for signs and symptoms, and to exclude shoulder pain
that is not due to rotator cuff origin (eg, neural or cervical
referral, adhesive capsulitis). Participants with bilateral
CRCP symptoms will be asked to indicate which shoulder
is the most symptomatic. This shoulder will be treated.
Those with equally symptomatic shoulders will receive
treatment for the shoulder of the dominant limb.
The Royal Melbourne Hospital Human Research Ethics
Committee approved the study (Project #2001.115) and
all participants will provide written informed consent.
Randomisation and allocation
Following a physical screening examination, volunteers
who meet the inclusion criteria will be accepted as partic-
ipants and undergo baseline assessment at the University
of Melbourne. Following baseline assessment, partici-
pants will be stratified by treatment site and randomly
assigned in permuted block of six and eight to either phys-
iotherapy or placebo treatment groups. The randomisa-
tion sequence will be generated using a computer-
generated table of random numbers by the study biostat-
istician (AF). Allocations will be sealed in opaque and
consecutively numbered envelopes kept in a locked loca-
tion. These will be opened in sequence by an independent
administrator not involved in eligibility assessment, out-
come assessment or treatment. Allocation will be revealed
to the treating physiotherapist by fax before the partici-
pant presents for treatment.
Interventions
Ten musculoskeletal physiotherapists located around
metropolitan Melbourne will implement both interven-
tions. All treatments will be individual sessions lasting
30–45 minutes, twice weekly for the first 2 weeks, once a
week for the next 4 weeks, then once a fortnight in the last
4 weeks (a total of 10 treatments). Participants will be
requested to refrain from seeking other forms of treatment
during the trial. However, due to ethical considerations,
analgesia will be permitted. Use of medications and other
therapies will be recorded in a logbook.
The treatments will be standardized and the therapists
will be trained to deliver both treatments prior to the
study. A comprehensive treatment manual will be pro-
duced and the importance of following the protocol
emphasised. For the physiotherapy treatment, it is consid-
ered important to allow the therapists to adjust the inten-BMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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Trial profile Figure 1
Trial profile.
Phone Screening 
Ineligible  
Fail inclusion criteria  
Meet exclusion criteria
Physical Screening 
Ineligible  
Fail inclusion criteria  
Meet exclusion criteria  
0 weeks     Consent, baseline assessment and 
randomisation 
Placebo
intervention 
Physiotherapy 
intervention 
10 weeks             Final assessment  
Home exercise  No treatment 
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sity of the standardised treatment techniques to match the
participants' capabilities. Thus the number of repetitions
of the exercises can be reduced. Deletion of techniques
will be permitted if participants find them too painful. At
the end of each treatment session for each participant, the
physiotherapist will complete a checklist to ensure com-
pliance with the standard approach.
All participants will be requested not to seek other forms
of treatment during the study but use of analgesia will be
permitted and recorded in a log-book.
Physiotherapy intervention group
A standardized treatment protocol has been devised (SC)
based on the literature and on the results of a formal writ-
ten survey we conducted involving 10 musculoskeletal
physiotherapists around Australia, considered by the pro-
fession to be experts in treating shoulder conditions.
These physiotherapists were asked to indicate which of a
series of interventions they would generally use at three
stages of a 10-week program when managing a typical
patient with CRCP. The results showed that the most com-
monly employed modalities were scapular retraining
(100%), rotator cuff exercises (100%), spinal (83%) and
shoulder joint mobilisation (50%), soft tissue massage
(66%) and taping (50%). Less emphasis is placed on elec-
trotherapy modalities (33%) with few using these, partic-
ularly past the first three weeks of treatment (Coburn et al
unpublished data).
The aims of the resultant physiotherapy intervention are
to i) decrease pain; ii) improve functional range of shoul-
der motion; iii) improve scapular control; iv) strengthen
scapular stabilisers and rotator cuff muscles; v) improve
posture and thoracic extension range of motion; vi) regain
normal shoulder biomechanics. The treatment has five
components comprising soft tissue massage, passive
mobilisation of the glenohumeral joint, scapula retrain-
ing, spinal mobilisation, and home exercises (Table 1).
Cognitive behavioural strategies will also be incorporated
including education, goal-setting, motivation and posi-
tive reinforcement.
Soft tissue massage
Deep massage of the soft tissue structures around the
shoulder joint will be performed for six minutes in two
positions. The posterior joint capsule and scapular shoul-
der musculature will be massaged in sidelying while the
anterior shoulder structures including the supraspinatus,
long head of biceps and pectoralis minor tendons will be
massaged in supine.
Glenohumeral joint mobilisation
Anteroposterior and inferior glenohumeral joint mobili-
sations will be performed with the participant in supine
and with the shoulder in 45 degrees abduction and 90
degrees abduction respectively [35]. Grade IV oscillations
(into 50% resistance) will be maintained for 30 seconds
and repeated four times.
Scapular retraining
The aim of scapular retraining is to improve control of
scapular movement, particularly to avoid excessive eleva-
tion and protraction, so as to optimise the functional
position of the shoulder. The therapist will passively guide
the participant from a neutral shoulder girdle posture to
an adducted, depressed position, then to an upwardly
rotated, elevated position. The participant will then per-
form the movement actively for several repetitions fol-
lowed by a 10 second hold in the adducted, depressed
posture. This will be repeated 5 times. Postural taping will
also be worn full time for the first two weeks. The therapist
will firstly apply a protective skin barrier followed by non-
rigid, hypoallergenic tape to provide skin protection, and
then rigid strapping tape for postural adjustments. The
shoulder taping technique aims to encourage a retracted,
depressed scapular  posture and thoracic extension.
Spinal joint mobilisations
Mobilisation techniques will be performed to improve
range of cervical and thoracic motion, particularly tho-
racic extension. They will include unilateral lower cervical
spine (C5-7) and central upper-mid thoracic spine (T1-8)
posteroanterior mobilisation techniques with the partici-
pant in prone lying [35]. The therapist will use a Grade IV
force at each level, on both sides for the cervical spine and
centrally for the thoracic spine. The duration of this treat-
ment will be four minutes for each technique.
Home exercises
These are predominantly designed to increase rotator cuff
and scapular muscle strength (Table 2). Most exercises
require the participant to incorporate their scapular
retraining with strengthening of the rotator cuff muscles.
Some exercises reinforce and facilitate correct posture.
These exercises will be taught and performed during each
treatment session and exercise progressions will be intro-
duced regularly throughout the course of the treatment
program. Resistance for specific exercises will be provided
by hand weights or elastic theraband. Participants will be
asked to perform the exercises daily, except during the first
week of treatment where exercises will be completed twice
per day. Compliance will be monitored via a weekly log
book completed by the participant. During the follow-up,
the physiotherapy group will be requested to continue
daily home exercises.
Placebo group
As for many procedural interventions, it is difficult to
design a placebo treatment that fully mimics a physiother-BMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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apy program. However, our aim is to control for the effect
of regular contact with a therapist, the belief that treat-
ment will assist CRCP and the therapeutic environment.
Participants in the placebo group will receive the same
number and length of visits as those in the physiotherapy
group but will receive only sham ultrasound and light
application of a non-therapeutic gel. Participants in the
placebo group will receive no instruction in exercise tech-
niques and no manual therapy. We have used an identical
placebo protocol in completed clinical trials of physio-
therapy for patellofemoral pain syndrome [36], knee oste-
oarthritis [37] and shoulder adhesive capsulitis [38]. In
these trials, between 68% to 83% of participants in the
placebo group thought they had received 'real' physiother-
apy or were unsure. Blinding index was 0.49 (bootstrap
95% CI 0.40 to 0.56), interpreted as moderate success of
blinding in one study [38]. The placebo participants will
not receive any intervention or complete any home exer-
cises during the 12 week follow-up period.
Blinding
To maintain blinding, the plain language statement and
consent procedures will inform participants that they
have an equal chance of receiving real or placebo physio-
therapy but will not disclose details of the actual treat-
ments. A blinded examiner will perform all outcome
assessments. Participant blinding will be optimised by
using a realistic placebo intervention and by ensuring par-
ticipants do not attend for treatments or assessments con-
currently. Participants will also be requested to refrain
from discussing their treatment with the outcome asses-
sor. At trial completion, participants will nominate which
group they believed they have been allocated to. The data
manager and statistician will be unaware of treatment
allocation until completion of analyses.
Outcome assessment
Demographic information will be collected including age,
sex, duration of symptoms, previous investigations and
treatment, history of medical conditions, and medication
use. Expectation of a beneficial treatment effect will be
scored on an ordinal scale from 1 to 5 with higher scores
indicating higher expectations.
A number of outcome measures will be collected for this
study (Table 3). A combined shoulder pain and disability
index (SPADI) will be used to measure changes in shoul-
der pain and function at final and follow-up time points.
This is a self-administered, shoulder-specific index con-
sisting of 13 items divided into two subscales: pain (five
items) and disability (eight items) [39]. Responses to each
item are recorded on a 11 point Likert scale where 0 = "no
pain" or "no difficulty" and 10 = "worst imaginable pain"
or "so difficult it required help" for the pain and disability
items respectively. The SPADI score is calculated by sum-
ming then averaging the two subscales to give a score out
of 100 (higher score more pain/disability). It has accepta-
ble test-retest reliability, construct validity and responsive-
ness [39-41]. We have confirmed the clinimetric
properties of this index and found it to be more respon-
sive than other shoulder-specific questionnaires (effect
sizes 1.01–1.69) (Buchbinder et al unpublished data).
Table 1: Components of the physiotherapy intervention
Treatment component Dosage
Soft tissue massage 6 mins each position
Anterior and posterior shoulder tissues performed in supine and 
sidelying respectively
Glenohumeral joint mobilisation 4 × 30 seconds each position
Anteroposterior and inferior joint glides in supine with shoulder at 
45° and 90° abduction respectively
Thoracic spine mobilisation (T1-8) Grade IV on each level – 4 mins in total
Performed in prone using a central posteroanterior technique
Cervical spine mobilisation (C5-7) Grade IV on each level – 4 mins in total
Performed in prone using unilateral posteroanterior technique on 
both sides
Scapular retraining Weeks 1 and 2 only
In sidelying, therapist passively moves shoulder through range from 
elevation/protraction to retraction/depression then assisted by 
participant then independently. Isometric holds in retraction/
depression
15 reps × 5 reps with 10 sec holds
Postural taping Continuous (day and night) for two weeks
Taping of the shoulders and scapula to encourage scapular retraction 
and depression and thoracic extension
Re-applied after one week by the therapist
Exercises Home program:
Supervised and performed as home program Twice daily in first two weeks
Once a day thereafterBMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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Average pain, worst pain and pain on three self-selected
activities (over the past week) will be measured by sepa-
rate 11-point numeric rating scales [12] numbered in 1
cm intervals. The amount of weakness, stiffness and inter-
ference with activities of daily living (over the past week)
will be measured similarly.
Participant perceived global rating of change overall and
in pain, strength, and stiffness (since commencement)
will be recorded on separate 5 point Likert scales (1-much
worse, 2-slightly worse, 3-no change, 4-slightly better, 5-
much better). Measuring participant perceived improve-
ment using a rating of change scale has been shown to be
Table 2: Description of specific exercises
Name Description Dosage Weeks 
performed
Scapular setting Sitting, isometric hold of scapula in retracted and depressed 
position
5 sec hold × 5 reps Week 1 then 
maintained in all 
exercises
Self-resisted isometric ER Standing sideways to wall. Upper arm squeezing a towel roll 
against body, elbow bent with forearm pushing into wall
5 sec hold × 5 reps Weeks 1&2
Active ER Sitting with shoulder in 45° Abd resting elbow and forearm 
on table in IR. Taking shoulder into ER
10 reps × 2 Week 1&2
Shoulder shrugs Standing with arms slightly abducted and actively elevating 
scapula then lowering slowly
10 reps × 2 handweight Week 1&2
Pectoralis minor stretch Supine with arms in 45° Abd and elbows bent to 90°. 
Shoulders rotate into ER to stretch muscle
5 reps with 10 sec hold × 2 Weeks 2–6
Wall push up Standing arms length from wall, hands at shoulder height 
and shoulders in 45° Abd. Body lowered to wall and then 
pushed away
5 reps × 2 Weeks 2–10
Chin tuck Standing with head and back against a wall. Chin tucked in 
toward neck
5 reps × 10 sec holds Week 2
Resisted external rotation Sidelying with affected shoulder uppermost, elbow bent to 
90° and holding weight in hand. Weight lifted up toward 
ceiling with upper arm against body
10 reps × 2 using hand 
weight
Week 2
Thoracic extension over towel Supine on a firm surface with arms by side and lying on 
towel roll placed horizontally on floor at level of maximum 
thoracic curve
1–3 mins hold Weeks 3–6
Resisted scapular setting – elbow 
extension with shoulder neutral
Standing, arm by side and elbow bent holding theraband 
attached in front at shoulder height. Elbow straightened and 
slowly flexed whilst keeping scapula in set position
10 reps × 2 using 
theraband
Weeks 3–6
Resisted external rotation Standing, elbow bent to 90° and forearm along stomach and 
holding onto theraband at waist height. Keeping elbow in to 
side, pulling against theraband to perform ER
10 reps × 2 using 
theraband
Weeks 3&4
Resisted internal rotation Standing, elbow bent to 90° and shoulder in ER and holding 
onto theraband at waist height. Keeping elbow in by side, 
pulling against theraband to perform IR
10 reps × 2 using 
theraband
Weeks 3&4
Resisted horizontal row Standing, both arms outstretched holding onto theraband 
attached at waist height. Both arms pulled back toward 
trunk with elbows flexed
10 reps × 2 using 
theraband
Weeks 3–10
Resisted external rotation in 
supported 90° Abd
Sitting with shoulder supported in 90° Abd on table and 
forearm resting on table holding a weight in hand. Weight 
lifted toward ceiling keeping elbow on table
10 reps × 2 using hand 
weight
Weeks 5&6
Resisted internal rotation in 
supported 90° Abd
Sitting with shoulder supported in 90° Abd on table and 
forearm resting on table holding theraband attached behind. 
Hand taken to table to perform IR
10 reps × 2 using 
theraband
Weeks 5&6
Corner stretch Standing with one hand on each corner wall at shoulder 
height and elbows bent. Leaning in toward corner to stretch 
anterior shoulder and thoracic spine
5 reps × 10 sec holds Weeks 5–10
Resisted scapular setting – elbow 
flexion
Standing with hands at chest height, elbows bent and 
holding onto theraband which is then stretched apart by 
trying to straighten both elbows
10 reps × 2 Weeks 7–10
Resisted external rotation in 
unsupported Abd
ER performed in standing with shoulder unsupported in 45° 
scapular plane, elbow bent and holding theraband attached 
in front
10 reps × 2 Weeks 7–10
Resisted internal rotation in 
unsupported Abd
IR performed in standing with shoulder unsupported in 45° 
scapular plane, elbow bent and holding theraband attached 
behind
10 reps × 2 Weeks 7–10
ER = external rotation; IR = internal rotation; Abd = abductionBMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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a clinically relevant and stable concept for interpreting
truly meaningful improvements from the individual per-
spective [42]. A successful outcome will be defined a pri-
ori as 'much better' on the rating scale.
Health-related quality of life will be measured using the
Medical Outcomes Study 36-item short form (SF-36) (8
subscales scaled from 0–100 where a higher score repre-
sents better health) [43]. This the most widely used
generic measure of health related quality of life and per-
mits comparison of the impact of disease and treatment
across studies and populations. The clinimetric properties
of the SF-36 have been well established on samples from
diverse populations [43,44]. We will also use the Assess-
ment of Quality of Life (AQoL) instrument. The AQoL
comprises 15 items on ordinal scales with four levels per
item covering five dimensions (illness, independent liv-
ing, social relationships, physical senses and psychologi-
cal wellbeing). It produces a single utility index that
ranges from -0.04 (worst possible health-related quality of
life) to 1.00 (full health-related quality of life). The AQoL
has strong psychometric properties [45,46]. The AQoL can
also be converted into a utility index to calculate quality
adjusted life years (QALY).
Isometric shoulder strength for shoulder abduction, inter-
nal and external rotation will be measured using the
Nicholas Manual Muscle tester (Lafayette, USA). For
shoulder abduction, participants will be positioned in
supine with the shoulder in 90 degrees of abduction and
the elbow flexed to 90 degrees. The dynamometer will be
positioned on the lateral surface of the distal humerus,
proximal to the lateral epicondyle. Measurements of exter-
nal and internal rotation will be performed in sitting with
the arm by the side against a folded towel, the elbow
flexed to 90 degrees and the forearm in midprone. The
dynamometer will be positioned on the distal forearm.
One warm up trial followed by three maximal contrac-
tions will be performed and the median reading taken. We
previously measured 12 people with CRCP on two occa-
sions three days apart. Intraclass correlation coefficient
(ICC 2,3) values were 0.95 for abduction, 0.96 for internal
rotation and 0.93 for external rotation indicating that test
retest reliability was excellent.
A number of other measures will be obtained (Table 3).
Participant compliance will be obtained by recording the
number of physiotherapy sessions attended (out of a max-
imum number of 10). Those in the physiotherapy group
will complete a daily log-book to record the number of
home exercise sessions completed. Adverse events and the
use of co-intervention will be recorded in a log-book and
by open-probe questioning by the assessor at trial comple-
tion. Log-books will be posted back to the assessor on a
monthly basis and checked for completion. At the final
and followup measurement time points, study partici-
pants will be asked to indicate which treatment they
Table 3: Outcome measures
Primary Outcomes Measurement
Shoulder pain and disability index (SPADI) 13 items scored on an 11 point Likert scale
Average pain over past week 11 point horizontal numeric rating scale (end descriptors of 0 = no pain 
and 10 = worst pain possible)
Participant perceived global rating of change overall Ordinal scale (1-much worse, 2-slightly worse, 3-no change, 4-slightly 
better, 5-much better)
Secondary Outcomes
Worst pain, and pain on 3 self selected activities in past week 11 point horizontal numeric rating scale (end descriptors of 0 = no pain 
and 10 = worst pain possible)
Amount of stiffness, weakness, and interference to activities of daily 
living in past week
11 point horizontal numeric rating scale
Participant perceived global rating of change in pain, strength, and 
stiffness
Ordinal scale (1-much worse, 2-slightly worse, 3-no change, 4-slightly 
better, 5-much better)
Health-related quality of life • SF-36
• Assessment of Quality of Life index (AQol)
Isometric muscle strength of shoulder abduction, internal rotation and 
external rotation
Hand held dynamometer
Other measures
Compliance • Number of therapy visits
• Physiotherapy group: Completion of home exercises via log-book
Adverse effects Log-book and open probe questionningBMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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believe they have received and reasons for that choice to
assess the success of blinding.
Information on direct health care costs, direct non-health
care costs and production losses over the 22 weeks will be
collected by a logbook posted back to the assessor on a
monthly basis and checked for completion. Direct health
care costs will include costs of physiotherapy attendance
(assumed zero in the placebo group), additional health
provider visits, tests, prescription and over the counter
medication, professional home care and hospitalisation.
These will be valued using published prices for medical
costs. Direct non-health care resources will include use of
paid and unpaid help, lost time and travel, and number of
lost days at work.
Sample size
Sample size was calculated based upon the ability to
detect a 10-point difference in improvement in SPADI
score, previously reported to indicate a clinically impor-
tant improvement (or worsening) of shoulder function
[41]. Applying power calculations appropriate for analysis
of covariance (adjusting for baseline SPADI score), to
detect a difference in 10 week SPADI of 10 units assuming
a common between-participant standard deviation of 27
and a baseline to 10 week correlation in SPADI scores of
0.45 (from our pilot study), 91 participants per group will
be required to achieve 80% power at a two-sided 5% sig-
nificance level. Including the 10 week and further 22 week
follow-ups in a repeated measures analysis increases the
power to 85% assuming a conservative correlation of 0.8
between all post-baseline measurements and a uniform
physiotherapy effect. We will allow for a 10% loss to fol-
low-up and aim to recruit 100 participants per group.
Data analysis
All analyses will be conducted on an intention-to-treat
principle using all randomized participants. Missing data
will be replaced by the last score carried forward. Demo-
graphic characteristics and baseline data will be summa-
rised by descriptive statistics. An index will be computed
to assess the success of blinding [47]. This index takes the
value one for complete blinding and zero for complete
lack of blinding.
For outcomes measured using an essentially continuous
scale, differences in mean change from baseline to each
time point will be compared between groups using linear
regression modelling adjusting for baseline levels of the
outcome measure. Model assumptions will be checked by
standard diagnostic plots [48]. For analysis across all time
points simultaneously, accounting for repeated measure-
ments, we will estimate the differences between groups
using generalised estimating equation models for the
post-baseline measurements with adjustment for baseline
measurements, a robust variance and unstructured work-
ing correlation [49]. Constancy of the difference between
groups over time will be assessed by fitting models which
include a term for the interaction between treatment and
time. Sensitivity analyses include repetition of analyses
with calculation of bootstrap standard errors, and identi-
fication of influential individuals by sequentially omit-
ting each participant and refitting the model.
Participant measures of perceived improvement following
physiotherapy or placebo treatments will be compared by
calculating the relative risks and their 95% confidence
intervals at each time point using log binomial regression
[50]. Repeated measures relative risk calculations will be
performed using generalised estimating equations with a
logarithmic link function, robust variance and unstruc-
tured correlation [49]. As above, models including a term
for the interaction between treatment and time will be fit
to assess the constancy of the difference between groups
over time.
The primary economic evaluation will take the form of a
cost effectiveness study with a range of outcome measures
including the incremental cost per extra person with a
clinically significant improvement in pain, per extra per-
son perceived to be recovered, and per extra quality
adjusted life years (using the AQoL over 22 weeks). A
social perspective on costs will be taken that includes
resource use incurred both by health services and by the
participant irrespective of the source of payment. The
inclusion of time/productivity gains is controversial and
the cost effectiveness ratios will be calculated with and
without these indirect costs. All health care costs will be
included, however to reduce the impact of extreme values,
if inpatient hospital costs are unrelated to CRCP they will
be excluded. Standard methods of economic evaluation
alongside a clinical trial [51] will be used to evaluate the
differences in resource use and health outcomes over 12
months between groups. The statistical analysis of costs
data will be similar to outcome data although adjust-
ments for overdispersion may be necessary. Confidence
intervals for incremental cost effectiveness will be calcu-
lated directly using non-parametric bootstrapping [52]. In
addition we will calculate a cost effectiveness acceptability
curve based for a range of hypothetical money values of
outcomes [53]. This will be done using individual cost
and outcome data over the 22 weeks or, if adjustments for
imbalance at baseline are necessary, using regression anal-
ysis [54]. Hypothetical money values will be taken from
the decision making literature but the trial will also ask
patients in each arm of the trial their willingness to pay for
the treatment prior to and after treatment. This will not
only provide money values for the calculation of net ben-
efits but also provide evidence on the influence of health
experience on the value of health outcome to patients.BMC Musculoskeletal Disorders 2007, 8:86 http://www.biomedcentral.com/1471-2474/8/86
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Discussion
This study uses a double-blind randomised controlled
trial design to investigate whether a multimodal physio-
therapy program has greater effects on pain, disability and
health-related quality of life and is more cost-effective
than placebo in people with CRCP. The benefits of physi-
otherapy for this patient group have not been well estab-
lished in the literature and there is no information on its
cost effectiveness.
At present there is no gold standard diagnostic test for
CRCP. Our criteria for inclusion into the study are based
on clinical assessment performed by a medical doctor and
a physiotherapist together with a shoulder xray to assist in
differential diagnosis. While imaging techniques such as
magnetic resonance imaging or ultrasound may further
improve diagnostic accuracy particularly if performed by
a single experienced operator [55], these still lack sensitiv-
ity for certain pathologic features [56,57] and are costly.
We wished to reflect the population that present to pri-
mary care for assessment and treatment and who in many
cases will not have these investigative procedures per-
formed.
Physiotherapy generally encompasses a multimodal
approach to treatment. Therapists utilise a variety of tech-
niques such as mobilisation, soft tissue massage, taping,
exercise prescription and education. As there is no 'gold
standard' physiotherapy for CRCP, we chose to use a
standardised program rather than employ a pragmatic
design whereby therapists chose the program based on
their own clinical reasoning and experience. This was
done to ensure a consistent approach and to allow repli-
cation of the program tested. A number of treating thera-
pists were included to increase the external validity of the
results.
We chose a placebo treatment as the comparator rather
than no treatment as we wished to evaluate the specific
effects of physiotherapy over and above those gained from
regular contact with a caring therapist. There is some
debate in the literature about whether it is appropriate to
use a placebo treatment for interventions such as physio-
therapy or acupuncture where it is difficult to isolate the
direct and indirect effects of the therapy [58]. It has been
argued that these effects are unlikely to be distinct, divisi-
ble and additive and that using a placebo controlled trial
design will not detect the whole treatment effect and may
generate false negative results. However, we believe that
the primary goal of physiotherapy is to improve the mod-
ifiable impairments associated with CRCP using various
techniques and as such it should provide greater benefits
than those simply due to the therapeutic environment.
The project physiotherapists will treat an equal propor-
tion of experimental and placebo group participants to
ensure that any effects of the personality of each therapist
and the treatment environment are equally distributed.
It is anticipated that all participants will be recruited by
the middle of 2007 with data acquisition completed six
months later. The results from this trial will contribute to
evidence based recommendations for the effectiveness of
a physiotherapy program in the management of CRCP.
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